WHO’s latestÌýgives an in-depth picture of the extent to which drug resistance is growing, and the steps that countries are taking to ensure people will receive effective medicine to treat and prevent HIV.
The report reveals that in 2020, 64% of focus countries (countries with a high burden of HIV infection) had national action plans to prevent, monitor and respond to HIV drug resistance.Ìý
These plans are informed by theÌý, a multi-stakeholder plan coordinated and published by WHO.
WHO encourages countries to monitor resistance and recommends that for people starting antiretroviral drugs (ARVs) calledÌýÌýÌý(PDR). WHO recommends that when PDR to non-nucleoside reverse transcriptase inhibitors (NNRTI) such as nevirapineÌýÌýand efavirenz reaches a threshold of 10% for a surveyed country, then the first-line HIV treatment should be urgently changed to a more robust dolutegravir-containing regimen.
This reportÌýindicates that an increasing number of countries are reaching the 10% threshold of PDR HIV drug resistance to NNRTIÌýand people who have had previous exposure to antiretroviral drugs are three times more likely to demonstrate resistance to the NNRTI drug class.Ìý
These findings emphasize the need to accelerate the transition to dolutegravir-containing regimens in countries that continue to use NNRTI-based antiretroviral therapy.Ìý
Based on the most recent findings from surveys conducted in 10 countries in sub-Saharan Africa, nearly half of infants newly diagnosed with HIV carry drug-resistant HIV before initiating treatment. These findings highlight the need to accelerate the ongoing transition and importance of using dolutegravir-based antiretroviral therapy in young children as early as possible.
- At the end of 2020, 27.5 million people were receiving antiretroviral therapy worldwide. HIV drug resistance can compromise the effectiveness of antiretroviral drugs in reducing HIV incidence and HIV-associated morbidity and mortality.
- Minimizing the spread of HIV drug resistance is a critical aspect of the broader global response to antimicrobial resistance that requires coordinated action across all governmental sectors and levels of society.
- In 21 of 30 surveys reported to WHO, pretreatment HIV drug resistance to nevirapine (NVP) or efavirenz (EFV) in populations initiating first-line ART reached levels above 10%.
- Pretreatment HIV drug resistance to the NNRTI drug class is up to 3 times more common in people with previous exposure to antiretroviral drugs.
- Nearly one half of infants born to mothers infected with HIV has HIV drug resistance to one or more NNRTIs.
- Global prevalence of resistance to the NNRTI drug class emphasizes the need to fast-track the transition to the newer dolutegravir-based regimens.
- Stopping HIV drug resistance is important to ensure the long-term efficacy and durability of available medicines to treat HIV.
- To stop HIV drug resistance all global stakeholders should promote the availability of optimal medicines to treat HIV infections, support retention in care and optimal adherence to treatment, increase access and use of viral load testing to know if HIV treatment is working, and rapidly switch regimens in cases of confirmed treatment failure.
​
Since 2019, WHO has recommended use of dolutegravir as the preferred first-and second-line of treatment for all population groups. It is more effective, easier to take, and has fewer side effects than other drugs currently in use.Ìý
Dolutegravir also has a high genetic barrier to developing drug resistance, thus supporting its long-term durability and effectiveness.Ìý
Since the surveys were implemented, many more countries have initiated transition to dolutegravir-containing regimens, providing people with a better treatment option and strengthening the fight against drug resistance.
Ìýis an effective prevention option for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches. Resistance is most likely to occur when PrEP is started in the setting of undiagnosed acute HIV infection.Ìý
As countries implement PrEP to prevent HIV infection, it should be accompanied by surveillance of HIV drug resistance in people who become infected despite use of PrEP.
The report indicates that the number of countries achieving high levels of viral suppression (≥90%) increased from 33% in 2017 to 80% in 2020. Achieving high levels of viral load suppression in populations taking antiretroviral therapy prevents transmission of HIV, HIV-associated morbidity and mortality and prevents emergence of HIV drug resistance.
Viral load monitoring
The report also emphasizes the need for routine viral load monitoring and close follow-up of individuals with viral non-suppression, including regimen switch if indicated, to achieve favourable and sustained long term treatment outcomes.Ìý
In addition, ensuring the continuous availability and accessibility to optimal medicines to treat HIV infections is essential to prevent HIV drug resistance.Ìý
These findings emphasize the need to support countries in proactively finding sustainable solutions that are appropriate to local contexts and can involve community members and civil society.
As the currentÌýÌýdraws to a close, the report recommends future global, national and country efforts to identify ongoing opportunities to prevent, monitor and respond to HIV drug resistance including adapting to the rapidly evolving treatment landscape and new service delivery models.Ìý
Minimizing the spread of HIV drug resistance is a critical aspect of the broader global response to antimicrobial resistance that needs coordinated action across all government sectors and levels of society.
"This now regular HIVDR report and surveillance holds countries accountable – to provide high quality HIV treatment and care and focused investment in AMR. In the future, we will expand our surveillance to new ARVs, and those that are delivered as long-acting agents for prevention and treatment – so that we can maintain our ARVs for the lifetime of people living with HIV," said Meg Doherty, Director of WHO’s Global HIV, Hepatitis and STI Programmes.
